| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/5000-1/10000 | Human,Mouse,Rat |
| Aliases | PLC; SJA; SJS; HSPG; SJS1; PRCAN |
| WB Predicted band size | 469 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Mouse |
| Immunogen | Synthetic peptide of human HSPG2 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是3篇关于HSPG2抗体的参考文献及其摘要概括：
1. **文献名称**：HSPG2 (Perlecan) expression in tumor angiogenesis studied by immunohistochemical co-localization
**作者**：Smith J, et al.
**摘要**：该研究通过HSPG2抗体免疫组化技术，发现肿瘤血管基底膜中HSPG2的高表达与血管生成活性正相关，提示其作为肿瘤治疗的潜在靶点。
2. **文献名称**：Antibody-based detection of HSPG2 mutations in congenital muscular dystrophy
**作者**：Tanaka K, et al.
**摘要**：开发了一种特异性HSPG2抗体，用于Western blot和免疫荧光检测，成功识别出先天性肌营养不良患者中HSPG2的截短蛋白，推动基因诊断技术优化。
3. **文献名称**：Targeting HSPG2 with neutralizing antibodies inhibits amyloid plaque formation in Alzheimer's models
**作者**：Chen R, et al.
**摘要**：研究发现抗HSPG2中和性抗体可阻断β-淀粉样蛋白与基底膜结合，显著减少阿尔茨海默病小鼠模型的斑块沉积，为治疗策略提供新方向。
---
*注：以上文献为示例性内容，实际引用需核实真实出版物。建议通过PubMed或Web of Science以"HSPG2 antibody"+"perlecan"为关键词检索最新研究。*
HSPG2 antibodies target heparan sulfate proteoglycan 2. a large extracellular matrix protein encoded by the *HSPG2* gene. Also known as perlecan, this multidomain proteoglycan is a key component of basement membranes and connective tissues. It consists of a core protein with attached heparan sulfate chains, enabling interactions with growth factors, cytokines, and other matrix components. Perlecan plays critical roles in tissue development, cell adhesion, angiogenesis, and mechanotransduction.
HSPG2 mutations are linked to genetic disorders like Schwartz-Jampel syndrome (characterized by skeletal dysplasia and myotonia) and dyssegmental dysplasia. Altered perlecan expression is also implicated in cancer progression, atherosclerosis, and fibrosis. Antibodies against HSPG2 are widely used in research to study its localization, expression patterns, and molecular interactions. They are essential tools in immunohistochemistry, Western blotting, and immunofluorescence to explore basement membrane integrity, tumor microenvironment changes, or disease mechanisms. Some therapeutic antibodies targeting HSPG2 domains are under investigation for modulating angiogenesis or drug delivery. Commercial HSPG2 antibodies are typically raised against specific epitopes in its core protein or glycosaminoglycan chains, with validation in human, mouse, or rat models. Careful validation remains crucial due to perlecan’s structural complexity and splice variants.
×
